Pfizer Stock – U.S. begins studying risk of allergic reactions to Moderna, Pfizer COVID-19 vaccines
April 7 (Reuters) – The U.S. National Institutes of Health said on Wednesday it had begun a mid-stage study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna Inc and Pfizer Inc. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Pfizer Stock – U.S. begins studying risk of allergic reactions to Moderna, Pfizer COVID-19 vaccines
Tags: Pfizer Stock
Stock Market
Latest News on C N N.